See more : Scout Gaming Group AB (publ) (SCTGF) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Valson Industries Limited (VALSONQ.BO) Income Statement Analysis – Financial Results
- Lassonde Industries Inc. (LSDAF) Income Statement Analysis – Financial Results
- Galileo Tech Ltd (GLTC.TA) Income Statement Analysis – Financial Results
- Eterna Therapeutics Inc. (BTX) Income Statement Analysis – Financial Results
- CMC Markets plc (CMCX.L) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
| Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
| Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
| Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
| EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
| Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
| Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
| Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants...
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2024 and provided an...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced top-line results from an open-label phase 2 study evaluating the safety and...
Compass Pathways to announce first quarter financial results on May 8, 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending...
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US's leading providers of innovative...
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of...
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports